

| Freedom of Information Reques | FOI 21-191 | 25 th May 2021 |
|-------------------------------|------------|---------------------------|
| | | |

1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:

The Health Board is only able to supply information by quantity and not by the number of patients treated. The items dispensed below are for the period 1st November 2020 to 30th April 2021:

- Aubagio (teriflunomide) 14mg 1 x 28 = 93
- Avonex (interferon beta-1a) = 0
- Betaferon (interferon beta-1b) = 0
- Brabio (glatiramer acetate) = 0
- Copaxone (glatiramer acetate) = 0
- Extavia (beta interferon-1b) = 0
- Fampyra (fampridine) 10mg MR 1 x 28 = 48
- Gilenya (fingolimod) 500micrograms 1 x 28 = 160
- Lemtrada (alemtuzumab) = 0
- Mavenclad (cladribine) $10mg 1 \times 6 = 14$
- Mayzent (siponimod) = 0
- Ocrevus (ocrelizumab) 300mg in 10ml IV vial = 162
- Plegridy (peginterferon beta-1a) Initiation Pre-filled Syr 2 Syr
 pack = 1
- Plegridy (peginterferon beta-1a) 125micrograms in 0.5ml 1 Prefilled Syr = 62
- Rebif (beta interferon-1a) = 0
- Tecfidera (dimethyl fumarate) 120mg 1 x 14 = 2
- Tecfidera (dimethyl fumarate) 240mg 1 x 56 = 396
- Tysabri (natalizumab) 300mg in 15ml 1 vial = 192
- Zeposia (ozanimod) = 0

2. How many patients have been treated with the following drugs in the past 4 months:

The Health Board is only able to supply information by quantity and not by the number of patients treated. The items dispensed below are for the period 1st January 2021 to 30th April 2021:

- Ajovy (fremanezumab) any disease = 0
- Aimovig (erenumab) any disease 70mg in 1ml Pre-filled Pen = 71
- Emgality (galcanezumab) any disease = 0

- Botulinum Toxin (i.e. Botox, Dysport, Xeomin) migraine ONLY = Botox 200units 1 vial = 86*
- * Please note that although Botox 200 units is licensed for migraine, the quantity stated may include other conditions as quantities dispensed are not attributed to a speciality.
- 3. How many patients have been treated in the past 4 months for the following conditions:
 - Chronic migraine (15+ headache days per month)
 - Episodic migraine (4-14 headache days per month)
 - Primary progressive multiple sclerosis (PPMS)
 - Secondary progressive multiple sclerosis (SPMS)

To allow for clinical coding completeness, the following data has been provided data for the period October 2020 – January 2021

- During the 4 month period above, 92 patients were treated with a primary diagnosis of migraine (ICD10 codes do not have specific codes for chronic and episodic migraine). The 92 patients had a total of 96 hospital spells.
- During the 4 month period above, 60 patients were treated with a primary diagnosis of multiple sclerosis (ICD10 codes do not have specific codes for the type of multiple sclerosis). These 60 patients had a total of 128 hospital spells.